Literature DB >> 8911879

Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women.

J C Koster1, W H Hackeng, H Mulder.   

Abstract

OBJECTIVE: The effects of vitamin D deficiency in osteopenic postmenopausal women treated with intermittent cyclical etidronate have been studied. Bone mass and biochemical parameters as bone markers were measured before and after one year of therapy with intermittent cyclical etidronate.
RESULTS: In 30 patients without vitamin D deficiency, bone mass in the lumbal spine and femoral neck was significantly increased compared to 28 vitamin D deficient patients. After cyclical intermittent etidronate therapy, serum osteocalcin and PTH were significantly increased in the vitamin D deficient patients, whereas in non-vitamin D deficient patients they did not change.
CONCLUSION: It is worthwhile measuring serum vitamin D before starting etidronate therapy and, in case of deficiency, to give vitamin D.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911879     DOI: 10.1007/s002280050175

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.

Authors:  A S Carmel; A Shieh; H Bang; R S Bockman
Journal:  Osteoporos Int       Date:  2012-01-12       Impact factor: 4.507

Review 2.  Patient adherence to osteoporosis medications: problems, consequences and management strategies.

Authors:  Alexandra Papaioannou; Courtney C Kennedy; Lisa Dolovich; Elaine Lau; Jonathan D Adachi
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

3.  Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.

Authors:  I A Campbell; J G Douglas; R M Francis; R J Prescott; D M Reid
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

4.  Vitamin D insufficiency does not affect response of bone mineral density to alendronate.

Authors:  D M Antoniucci; E Vittinghoff; L Palermo; D M Black; D E Sellmeyer
Journal:  Osteoporos Int       Date:  2008-11-29       Impact factor: 4.507

5.  Value of a new fixed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis: results of two quantitative patient research studies.

Authors:  Johann D Ringe; Patrice Fardellone; Hans-Peter Kruse; Michael Amling; Stefan A P van der Geest; Gerd Möller
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone.

Authors:  Edward P Weiss; Krupa Shah; Luigi Fontana; Charles P Lambert; John O Holloszy; Dennis T Villareal
Journal:  Am J Clin Nutr       Date:  2009-03-25       Impact factor: 7.045

Review 7.  The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report.

Authors:  S Boonen; R Rizzoli; P J Meunier; M Stone; G Nuki; U Syversen; M Lehtonen-Veromaa; P Lips; O Johnell; J-Y Reginster
Journal:  Osteoporos Int       Date:  2004-07       Impact factor: 4.507

Review 8.  Bisphosphonates, vitamin D, parathyroid hormone, and osteonecrosis of the jaw. Could there be a missing link?

Authors:  Ignacio-Osoitz Leizaola-Cardesa; Antonio Aguilar-Salvatierra; Maximino Gonzalez-Jaranay; Gerardo Moreu; María-José Sala-Romero; Gerardo Gómez-Moreno
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2016-03-01

Review 9.  Schemes for Drug-Induced Treatment of Osteonecrosis of Jaws with Particular Emphasis on the Influence of Vitamin D on Therapeutic Effects.

Authors:  Filip Michalak; Sylwia Hnitecka; Marzena Dominiak; Kinga Grzech-Leśniak
Journal:  Pharmaceutics       Date:  2021-03-08       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.